Top Page
Vectus Biosystems Limited
(Sydney:VBS)
Vectus Biosystems Limited (VBS) vs. iShares MSCI Australia ETF (EWA)
Vectus Biosystems Limited Business Overview & Revenue Model
Vectus Biosystems Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 478.18K | 478.18K | 1.14M | 1.35M | 1.30M | 180.00 |
| Gross Profit | 478.18K | 478.18K | 1.14M | 1.31M | 1.28M | 1.02M |
| EBITDA | -1.69M | -1.69M | -2.27M | -3.19M | -3.28M | -3.71M |
| Net Income | -1.78M | -1.78M | -2.34M | -3.45M | -3.99M | -3.86M |
Balance Sheet | ||||||
| Total Assets | 782.66K | 782.66K | 2.03M | 4.63M | 3.94M | 6.98M |
| Cash, Cash Equivalents and Short-Term Investments | 250.99K | 250.99K | 808.97K | 2.95M | 1.28M | 5.78M |
| Total Debt | 200.00K | 200.00K | 28.93K | 70.21K | 6.90M | 8.68M |
| Total Liabilities | 1.04M | 1.04M | 539.26K | 1.11M | 8.36M | 9.88M |
| Stockholders Equity | -256.62K | -256.62K | 1.49M | 3.52M | -4.42M | -2.90M |
Cash Flow | ||||||
| Free Cash Flow | -830.09K | -830.09K | -2.10M | -2.37M | -4.46M | -3.26M |
| Operating Cash Flow | -830.09K | -830.09K | -2.03M | -2.35M | -4.44M | -3.26M |
| Investing Cash Flow | 101.03K | 101.03K | -67.90K | -17.13K | -21.00K | 0.00 |
| Financing Cash Flow | 171.07K | 171.07K | -41.28K | 4.04M | -34.55K | 6.35M |
Vectus Biosystems Limited Technical Analysis
Vectus Biosystems Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | AU$5.87M | -3.29 | -289.05% | ― | ― | 24.09% | |
40 Underperform | AU$2.17M | -4.33 | -28.49% | ― | ― | 46.43% | |
37 Underperform | AU$6.89M | -1.61 | -628.72% | ― | ― | 31.87% | |
36 Underperform | AU$7.23M | -27.50 | -184.73% | ― | ― | 87.88% | |
27 Underperform | AU$4.39M | -1.46 | -205.70% | ― | ― | 1.03% |
Vectus Biosystems Limited Corporate Events
Vectus Biosystems Limited has issued 75,000 new fully paid ordinary shares following the exercise of options under its Employee Incentive Plan. This move reflects the company’s compliance with regulatory requirements and showcases its efforts to incentivize employees and contractors, potentially impacting its operational dynamics and stakeholder relations positively.
Vectus Biosystems Limited has announced the quotation of 75,000 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move follows the exercise of options or conversion of other convertible securities, potentially enhancing the company’s capital structure and market presence.
Vectus Biosystems Limited held its Annual General Meeting on November 26, 2025, where all proposed resolutions were passed. These included the re-election of Ronald Shnier as a director, the election of Linda Walters as a director, and the adoption of the remuneration report. The successful passing of these resolutions indicates strong shareholder support and may positively impact the company’s governance and strategic direction.
Vectus Biosystems Limited announced progress in its commercialization efforts, particularly with its lead compound VB0004, which has shown safety and tolerability in Phase Ia and Ib trials. The company signed a binding term sheet with XORTX Therapeutics for the sale of its VB4-P5 compound, which will provide Vectus with shares in XORTX, allowing continued interest in the compound’s development without further financial contributions. This strategic move is expected to enhance shareholder value and expand opportunities in the pharmaceutical market.
Vectus Biosystems Limited has responded to an ASX price query, stating that it is unaware of any undisclosed information that could explain recent trading activity in its securities. The company confirms compliance with ASX Listing Rules and assures that its responses have been authorized by its board, maintaining transparency and adherence to regulatory standards.
Vectus Biosystems Limited has signed a binding agreement with XORTX Therapeutics Inc. for the sale of its VB4-P5 Renal Small Molecule Compound, a move that aligns with its strategy to develop and validate drug candidates for commercial partnerships. The company is also actively pursuing licensing opportunities, particularly in China, and is focused on reducing operational costs while exploring collaborations to fund further clinical studies, reflecting its commitment to advancing its anti-fibrotic therapies.
Vectus Biosystems Limited has announced its 2025 Annual General Meeting (AGM) will be held virtually on November 26, 2025. The meeting will cover several key business items, including the consideration of financial statements, the re-election of Dr. Ronald Shnier, the election of Ms. Linda Walters as directors, and the adoption of the remuneration report. The AGM provides shareholders with an opportunity to engage with the company’s leadership and discuss strategic directions, potentially impacting future company operations and stakeholder interests.
Vectus Biosystems Limited has announced the lifting of its trading suspension on the Australian Securities Exchange following a significant transaction involving a compound from its drug library. This development is expected to have a positive impact on the company’s operations and may enhance its positioning within the biotechnology sector, potentially benefiting stakeholders.
Vectus Biosystems Limited has entered into a binding agreement with XORTX Therapeutics Inc. for the sale of its VB4-P5 renal compound, which targets renal fibrosis. The transaction, valued at approximately A$4.5 million, will provide Vectus with shares and pre-funded warrants in XORTX, aligning with its strategy to develop and validate drug candidates for commercial partnerships. This deal allows Vectus to maintain an interest in the compound’s development without further financial input, while continuing to focus on its lead cardiovascular candidate and other emerging fibrosis treatments.
Vectus Biosystems Limited has voluntarily suspended its securities from trading on the ASX pending an announcement regarding a significant transaction involving one of its compounds. This suspension is intended to remain in place until October 21, 2025, or until the company makes the anticipated announcement, which could have implications for its operational strategy and market positioning.
Vectus Biosystems Limited has requested a trading halt on its securities pending an announcement regarding a significant transaction involving a compound from its drug library. This move suggests a potential strategic development that could impact the company’s market positioning and stakeholder interests, with further details expected before the resumption of trading.
Vectus Biosystems Limited has released its Corporate Governance Statement for the period from July 2024 to June 2025, highlighting its adherence to ASX corporate governance principles. The company acknowledges that while it strives to comply with these guidelines, certain recommendations are not feasible due to its size. The Board, supported by various committees, oversees governance, ensuring transparency and accountability in its operations.
Vectus Biosystems Limited has released its annual financial report, which includes consolidated financial statements and notes. The report, authorized by the Board of Directors, reflects the company’s financial activities and performance in Australian dollars, providing stakeholders with insights into its fiscal health and strategic direction.